JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: A tissue microarray-based study

Lu, Jeng‐Wei; Ho, Yi Jung; Lin, Liang In; Huang, Yen Chi; Yeh, Kun Tu; Lin, Yaw Huei; Tzeng, Tsai Yu

doi:10.1016/j.acthis.2014.10.002

Cited by 14 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is noteworthy that some of these genes have been reported in previous studies of cancer. KDM4B represents a novel prognostic factor for resected lung adenocarcinoma and a potential diagnostic marker for human hepatocellular carcinoma . Several studies have demonstrated that MAP2K5 plays an important role in the development of prostate cancer , breast cancer , and hepatocellular carcinoma .…”

Section: Discussionmentioning

confidence: 99%

Establishment of a nine‐gene prognostic model for predicting overall survival of patients with endometrial carcinoma

Ying

Wang

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

Endometrial carcinoma (EC) is the most common malignant tumor of the female genital tract in developed countries. The prognosis of early stage EC is favorable, but a subset faces high risk of cancer progression or recurrence. EC has a poor prognosis upon progression to advanced or metastatic stages. Therefore, our goal is to build a robust prognostic model for predicting overall survival (OS) in EC patients. In this study, 1571 genes were identified as being associated with OS based on genomewide expression profiles using a training dataset. Kyoto Encyclopedia of Genes and Genomes enrichment analysis revealed that these genes were involved in various cancer‐related signaling pathways. Nine signature genes were further selected using stepwise selection, and their potential role in the development of EC was demonstrated by performing differential expression analysis between EC and normal uterine tissues. A prognostic model that aggregated these nine signature genes was ultimately established and effectively divided EC patients into two risk groups. OS for patients in the high‐risk group was significantly poorer compared with that of the low‐risk group. This nine‐gene model was subsequently validated and evaluated using the TCGA dataset and shown to have a high discriminating power to distinguish EC patients with an elevated risk of mortality based on the FIGO staging system and other prognostic factors. This study provides a novel prognostic model for the identification of EC patients with elevated risk of mortality and will help to improve our understanding of the underlying mechanisms involved in prognostic EC factors.

show abstract

Section: Discussionmentioning

confidence: 99%

Establishment of a nine‐gene prognostic model for predicting overall survival of patients with endometrial carcinoma

Ying

Wang

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…For instance, increased KDM3A expression was associated with tumour recurrence after resection, 119 while the upregulation of LSD1/KDM1, KDM5B, KDM6B, KDM4B and KDM2A has been related to tumour aggressiveness and poor prognosis. [120] , [121] , [122] , [123] , [124] The transcriptional programmes influenced by the overexpression of KDMs are complex to elucidate. The activity of these enzymes may have differential effects on gene expression depending on the specific histone residue on which they act.…”

Section: Epigenetic Alterations In Hepatocarcinogenesismentioning

confidence: 99%

Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg

et al. 2020

View full text Add to dashboard Cite

Summary Hepatocellular carcinoma (HCC) is a deadly tumour whose causative agents are generally well known, but whose pathogenesis remains poorly understood. Nevertheless, key genetic alterations are emerging from a heterogeneous molecular landscape, providing information on the tumorigenic process from initiation to progression. Among these molecular alterations, those that affect epigenetic processes are increasingly recognised as contributing to carcinogenesis from preneoplastic stages. The epigenetic machinery regulates gene expression through intertwined and partially characterised circuits involving chromatin remodelers, covalent DNA and histone modifications, and dedicated proteins reading these modifications. In this review, we summarise recent findings on HCC epigenetics, focusing mainly on changes in DNA and histone modifications and their carcinogenic implications. We also discuss the potential drugs that target epigenetic mechanisms for HCC treatment, either alone or in combination with current therapies, including immunotherapies.

show abstract

“…Upregulation of KDM4B in PC cells was hypothesized to heighten the sensitivity of AR signaling in CRPC under castrated levels of androgen [9]. In addition, KDM4B has been shown to play a tumor‐promoting role in several types of carcinoma such as gastric [7], hepatocellular [10], and breast [11]. However, understanding of the interaction between AR and KDM4B in next‐generation anti‐androgen resistance remains elusive.…”

Section: Introductionmentioning

confidence: 99%

Targeting the KDM4B–AR–c‐Myc axis promotes sensitivity to androgen receptor‐targeted therapy in advanced prostate cancer

Tang

Dai

et al. 2020

The Journal of Pathology

View full text Add to dashboard Cite

The histone demethylase KDM4B functions as a key co‐activator for the androgen receptor (AR) and plays a vital in multiple cancers through controlling gene expression by epigenetic regulation of H3K9 methylation marks. Constitutively active androgen receptor confers anti‐androgen resistance in advanced prostate cancer. However, the role of KDM4B in resistance to next‐generation anti‐androgens and the mechanisms of KDM4B regulation are poorly defined. Here we found that KDM4B is overexpressed in enzalutamide‐resistant prostate cancer cells. Overexpression of KDM4B promoted recruitment of AR to the c‐Myc (MYC) gene enhancer and induced H3K9 demethylation, increasing AR‐dependent transcription of c‐Myc mRNA, which regulates the sensitivity to next‐generation AR‐targeted therapy. Inhibition of KDM4B significantly inhibited prostate tumor cell growth in xenografts, and improved enzalutamide treatments through suppression of c‐Myc. Clinically, KDM4B expression was found upregulated and to correlate with prostate cancer progression and poor prognosis. Our results revealed a novel mechanism of anti‐androgen resistance via histone demethylase alteration which could be targeted through inhibition of KDM4B to reduce AR‐dependent c‐Myc expression and overcome resistance to AR‐targeted therapies. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

show abstract

JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: A tissue microarray-based study

Cited by 14 publications

References 29 publications

Establishment of a nine‐gene prognostic model for predicting overall survival of patients with endometrial carcinoma

Establishment of a nine‐gene prognostic model for predicting overall survival of patients with endometrial carcinoma

Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg

Targeting the KDM4B–AR–c‐Myc axis promotes sensitivity to androgen receptor‐targeted therapy in advanced prostate cancer

Contact Info

Product

Resources

About